( QUEBEC CITY April 13 2007 /PRNewswir...)AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles,Health

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two abstracts outlining first in vitro data on its PI3K inhibitors as well as in vivo data on its GHRH antagonist, JMR-132, which both may potentially provide new therapeutic approaches for the treatment of cancer. These abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 14-18 at the Los Angeles Convention Center in Los Angeles, California.

    Selected abstracts for poster sessions in the Exhibit Hall:


    Monday, April 16, 8:00 a.m. - 12:00 p.m. (PT)

        - Abstract #2379 "New Generation of Anilino-Substituted

          Pyridopyrazine-Urea Derivatives Show Highly Selective PI3K-

          Inhibition". Irene Seipelt, Eckhard Claus, Tilman Schuster,

          Emmanuel Polymeropoulos, Michael Teifel, Eckhard Gunther.

          The abstract reviews, for the first time, results of a preclinical

          development program on a new generation of pyridopyrazine

          derivatives which clearly indicate that these drug candidates

          selectively inhibit PI3K and could be valuable for the treatment of

          cancer.


    Tuesday, April 17, 8:00 a.m. - 12:00 p.m. (PT)

        - Abstract #3568 "GHRH-Antagonist in Combination with Docetaxel

          Chemotherapy induces regression of MX-1 human experimental breast

          cancers". Joerg B. Engel, Andrew V. Schally, Jozseph Varga, Gabor

          Halmos, Stefan Buchholz.

          The abstract reviews results which demonstrate that GHRH

          antagonist, JMR-132, inhibits doxorubicin resistant in MX-1 human

          breast cancers and induces growth arrest or total regression when

          combined with docetaxel chemotherapy. Consequently, JMR-132 could

          provide a new therapeutic approach for t
'"/>




Page: 1 2 3 
Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2
Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist
JMR-132 at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris Discloses First In Vitro Data for its PI3K
Inhibitors at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH
for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K

Inhibitors at the AACR Annual Meeting in Los Angeles
7. The Past, Present and Future of HLA Typing
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
9. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society